ANG Lifesciences India Share Price
34.09+0.66 (+1.97%)
+34.96% past 1 Year
ANG Lifesciences India is ISO-9001:2008 certified and has the modern & sophisticated plant equipments technique and manpower. The planning and construction of plant has been done to conform to the
Corporate filings & documents
Announcements
Financial Results 30.06.2026.
2 weeks agoFinancial Results 30.06.2026.
2 weeks agoSubmission of standalone and consolidated unaudited financial results for the quarter ended on 30.06.2026 under Regulation 33 of the SEBI (LODR) Regulations 2015
2 weeks agoSubmission of standalone and consolidated unaudited financial results for the quarter ended on 30.06.2026 under Regulation 33 of the SEBI (LODR) Regulations 2015
2 weeks agoANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results for the quarter ended June 30 2026.
4 weeks agoANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results for the quarter ended June 30 2026.
4 weeks agoReg 74(5) Certificate
1 month agoReg 74(5) Certificate
1 month agoClosure of Trading Window
2 months agoClosure of Trading Window
2 months agoNewspaper Publication of Audited Financial Results for the quarter and year ended March 31 2026.
3 months agoNewspaper Publication of Audited Financial Results for the quarter and year ended March 31 2026.
3 months agoAudited Results 31.03.2026
3 months agoAudited Results 31.03.2026
3 months agoAudited Financial Results for the quarter and year ended 31st March 2026
3 months agoAudited Financial Results for the quarter and year ended 31st March 2026
3 months agoAnnual Secretarial Compliance Report 31.03.2026.
3 months agoAnnual Secretarial Compliance Report 31.03.2026.
3 months agoANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 inter alia to consider and approve the Standalone & Consolidated Audited Financial Results for the 4th Quarter and Financial Year Ended March 31 2026.
3 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>ANG Lifesciences India Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24230PB2006PLC030341</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Harshita Aggarwal <br/> Designation: Company Secretary <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Saruchi Gupta <br/> Designation: Chief Finnancial Officer <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 17/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>ANG Lifesciences India Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24230PB2006PLC030341</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Harshita Aggarwal <br/> Designation: Company Secretary <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Saruchi Gupta <br/> Designation: Chief Finnancial Officer <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 17/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months agoCertificate under Reg 74(5) of SEBI (DP) Regulations 2018
4 months agoThis is with reference to the email communication received from BSE Limited on April 09 2026 seeking clarification for a significant movement in the price of the securities of the company.
4 months agoThis is with reference to the email communication received from BSE Limited on April 09 2026 seeking clarification for a significant movement in the price of the securities of the company.
4 months agoThe Exchange has sought clarification from ANG Lifesciences India Ltd on April 9 2026 with reference to significant movement in price in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.<BR><BR>The reply is awaited.
4 months agoThe Exchange has sought clarification from ANG Lifesciences India Ltd on April 9 2026 with reference to significant movement in price in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.<BR><BR>The reply is awaited.
4 months agoIntimation of closure of Trading Window.
5 months agoUnaudited Financial Results 31.12.2025.
6 months agoUnaudited Financial Results 31.12.2025.
6 months agoApproval Of Unaudited Financial Results For The Quarter And Nine Months Ended 31-12-2025
6 months agoApproval Of Unaudited Financial Results For The Quarter And Nine Months Ended 31-12-2025
6 months agoRevised Annual Secretarial Report for the year ended 31.03.2025.
6 months agoANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended on 31st December 2025.
7 months agoDisclosure under Reg. 74(5) of SEBI (DP) Regulations 2018.
7 months agoClosure of Trading Window.
8 months agoUnaudited Financial Results for the Quarter and Half year ended 30.09.2025.
9 months agoConsidered and approved the financial results for the quarter and half year ended 30th September 2025
9 months agoANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve Pursuant to the Regulation 29 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 It is hereby informed you that the meeting of the Board of Directors of the Company is scheduled to be held on Friday 14th November 2025 at 05:00 P.M. at the Registered Office of the Company situated at Darbara Complex SCO-113 District Shopping Centre B Block Ranjit Avenue Amritsar-143001 inter alia transact the following business:1. To consider and approve the Standalone and Consolidated Un-Audited Financial Results of the Company for the quarter and half year ended 30th September 2025.2. Any other business that may be necessary with the permission of Chairman.
10 months agoCertificate under Reg 74(5) of SEBI (DP) Regulations 2018
10 months agoScrutinizers Report along with voting Results
11 months agoAppointment of Secretarial Auditor
11 months agoProceedings of the 19th AGM of the company are enclosed herewith.
11 months agoClosure of Trading Window
11 months agoClarification on Price Movement
11 months agoThe Exchange has sought clarification from ANG Lifesciences India Ltd on September 12 2025 with reference to significant movement in price in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.<BR><BR>The reply is awaited.
11 months agoNewspaper Advertisment for the Notice of 19th AGM
11 months agoAnnual Report for the FY 2024-25
12 months agoNotice of AGM is Enclosed
12 months agoIntimation of Book Closure
12 months agoIntimation of AGM
12 months agoAnnual reports
Concalls & investor presentations
Aug 2022
ConcallPresentation
Feb 2022
ConcallPresentation
Oct 2021
ConcallPresentation
Jun 2021
ConcallPresentation
Corporate Actions
Date
Type
Details
No data available.
Company details
Registered office
Darbara Complex, Sco 113, First Floor District Shopping Centre B Block Ranjit Avenue Amritsar Punjab PIN: 143001 Tel No: 0183 5133455 / 5133473 Fax No: NULL Email: [email protected] Internet: www.anglifesciences.com
Registrars
E-2, Ansa Industrial Estate, Saki Vihar Road, Saki Naka, Mumbai Maharashtra E-2/3, Ansa Industrial Estate Saki Vihar Road Saki Naka PIN: Tel No: 91-022–62638200 Fax No: NULL Email: NULL Internet: www.bigshareonline.com
Management
Rajesh Gupta, Managing Director
Saruchi Gupta, Whole Time Director
Sukhpal Singh, Non Executive Independent Director
Harvinder Singh, Non Executive Independent Director
Chetna, Non Executive Independent Director
Rohit Mittal, Non Independent & Non Executive Director
Harshita Aggarwal, Company Secretary & Compliance Officer
Details
BSE 540694
NSE NULL
ISIN INE236W01016